07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Bamosiran: Phase II data

Top-line data from the double-blind, international Phase II SYLTAG trial in 184 patients with open-angle glaucoma or ocular hypertension and a baseline IOP of >=23 mmHg showed that once-daily 0.375%, 0.75%, 1.125% and 1.5% bamosiran...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

SYL040012: Phase IIa data

A double-blind, dose-ranging, European Phase IIa trial in 80 patients with ocular hypertension or open-angle glaucoma showed that once-daily 300 µg SLY040012 eye drops for 14 days met the primary endpoint of reducing IOP from...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

SYL040012: Phase II started

Sylentis said it began a placebo-controlled, dose-ranging, European Phase II trial to evaluate daily SYL040012 eye drops for 14 days in 80 patients. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Sylentis...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

SYL040012: Phase I/II started

Zeltia's Sylentis S.A. subsidiary began an open-label, Spanish Phase I/II trial to evaluate SYL040012 ophthalmic drops administered once daily for 7 days in 30 patients. Zeltia S.A. (Madrid:ZEL), Madrid, Spain   Product: SYL040012   Business: Ophthalmic...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

SYL040012: Phase I/II start

Next month, Zeltia's Sylentis S.A. subsidiary plans to begin a single-blind, Spanish Phase I/II trial to evaluate SYL040012 ophthalmic drops given once daily in 30 patients. Zeltia S.A. (Madrid:ZEL), Madrid, Spain   Product: SYL040012...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

SYL040012: Phase Ia data

Zeltia's Sylentis S.A. subsidiary reported data from 30 healthy volunteers in a single-blind, Spanish Phase Ia trial showing that subjects displayed "excellent" local and systemic tolerance to SYL040012 ophthalmic drops. The company said it...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

Zeltia preclinical data

In a rabbit model of hypertension, SYL040012 prevented intraocular pressure increase and ocular hypertension induced by oral gravage. Data on the topically administered siRNA against adrenergic receptor beta 2 (ADRB2) were presented at the...